NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

GeneDx logo
$45.46 -3.78 (-7.68%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$45.42 -0.04 (-0.09%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About GeneDx Stock (NASDAQ:WGS)

Advanced

Key Stats

Today's Range
$45.16
▼
$49.10
50-Day Range
$45.46
▼
$104.95
52-Week Range
$32.21
▼
$170.87
Volume
912,293 shs
Average Volume
1.14 million shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.14
Consensus Rating
Moderate Buy

Company Overview

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results.

The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk.

Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care. The company is based in the United States and serves healthcare providers and patients through its diagnostic services.

AI Generated. May Contain Errors.

GeneDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

WGS MarketRank™: 
3.013489083575 of 5 stars

GeneDx scored higher than 60% of companies evaluated by MarketBeat, and ranked 260th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    GeneDx has a consensus price target of $90.14, representing about 98.3% upside from its current price of $45.46.

  • Amount of Analyst Coverage

    GeneDx has only been the subject of 4 research reports in the past 90 days.

  • Read more about GeneDx's stock forecast and price target.
  • Earnings Growth

    Earnings for GeneDx are expected to grow in the coming year, from ($0.37) to $1.26 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GeneDx is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GeneDx is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GeneDx has a P/B Ratio of 5.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    29.36% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 7.27.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 8.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GeneDx does not currently pay a dividend.

  • Dividend Growth

    GeneDx does not have a long track record of dividend growth.

  • News Sentiment

    GeneDx has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for GeneDx this week, compared to 8 articles on an average week.
  • Search Interest

    10 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,056.00 in company stock.

  • Percentage Held by Insiders

    25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GeneDx's insider trading history.
Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WGS Stock News Headlines

GeneDx (NASDAQ:WGS) Stock Rating Reaffirmed as Buy by BTIG Research
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
GeneDx Holdings Corp. Announces Management Changes
GeneDx Announces Leadership Transition
GeneDx Earnings Call Highlights Growth and Profitability
See More Headlines

WGS Stock Analysis - Frequently Asked Questions

GeneDx's stock was trading at $130.06 at the start of the year. Since then, WGS shares have decreased by 65.0% and is now trading at $45.46.

GeneDx Holdings Corp. (NASDAQ:WGS) released its quarterly earnings data on Monday, November, 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.07 by $0.21. The company had revenue of $123.10 million for the quarter, compared to analyst estimates of $122.93 million. GeneDx had a negative net margin of 24.10% and a positive trailing twelve-month return on equity of 1.98%.
Read the conference call transcript
.

GeneDx shares reverse split on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional shareholders of GeneDx include William Blair Investment Management LLC (5.23%), Sumitomo Mitsui Trust Group Inc. (2.22%), Assenagon Asset Management S.A. (2.12%) and State Street Corp (1.78%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Katherine Stueland, Kevin Feeley, Kareem Saad, Joshua Ruch, Jason Ryan and Bryan Dechairo.
View institutional ownership trends
.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), CrowdStrike (CRWD), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

Last Earnings
11/09/2026
Today
11/21/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:WGS
CIK
1818331
Fax
N/A
Employees
1,300
Year Founded
2000

Price Target and Rating

High Price Target
$150.00
Low Price Target
$63.00
Potential Upside/Downside
+98.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
36.08
P/E Growth
N/A
Net Income
-$21.02 million
Net Margins
-24.10%
Pretax Margin
-24.14%
Return on Equity
1.98%
Return on Assets
1.02%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
4.16
Quick Ratio
3.85

Sales & Book Value

Annual Sales
$427.54 million
Price / Sales
3.19
Cash Flow
$2.04 per share
Price / Cash Flow
22.26
Book Value
$8.16 per share
Price / Book
5.57

Miscellaneous

Outstanding Shares
29,970,000
Free Float
22,428,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
2.00

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:WGS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners